Lupus Science & Medicine

Controlling cardiovascular risk factors reduces progression of atherosclerosis in a multiethnic cohort of patients with lupus

Objective Patients with SLE have increased risk of both clinical cardiovascular disease (CVD) and subclinical atherosclerosis ...
Lupus Science & Medicine

Forgotten costs of systemic lupus erythematosus: estimating indirect healthcare costs in a national prospective observational Canadian lupus cohort

Objectives To assess indirect costs (IDC) due to lost productivity in paid/unpaid labour, stratified by sex, in a national ...
lupus.bmj

Informing trial measurement in systemic lupus erythematosus: frequency of domain-specific disease activity in a multinational cohort

Objective To report the prevalence of disease activity in individual SLE organ domains, including prevalence stratified by the most common disease activity cut-off score for clinical trial eligibility ...
lupus.bmj

Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-132

Background Circulating, extracellular RNA is the primary trigger of type I interferon in systemic lupus erythematosus (SLE), and interferon is known to play a central pathogenic role in the disease.
lupus.bmj

HNF-1β alleviates podocyte injury in lupus nephritis by maintaining endoplasmic reticulum homeostasis

Objective The current study aims to elucidate the critical function of hepatocyte nuclear factor 1-beta (HNF1-β) in lupus nephritis (LN) by investigating its modulation of the ...
lupus.bmj

Amelioration of renal injury by Qihuang Jianpi Zishen Granules in lupus mice is correlated with AMPK/ULK1-dependent modulation of macrophage polarisation

Objective To investigate the effects of Qihuang Jianpi Zishen Granules (QJZG) on renal injury in SLE mice, focusing on macrophage M1/M2 polarisation mediated by the AMPK/ULK1 signalling pathway.
lupus.bmj

Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE

Background Reports of clinical improvement following mesenchymal stromal cell (MSC) infusions in refractory lupus patients at a single centre in China led us to perform an explorative phase I trial of ...
lupus.bmj

Prevalence of sarcopenia and its association with clinical features and health-related quality of life in Brazilian women with systemic lupus erythematosus

Objectives To assess the prevalence of sarcopenia and examine its association with clinical features, health-related quality of life (HRQoL), muscle-specific strength and body composition in patients ...
lupus.bmj

SLE-DAS enables an accurate definition of severe lupus disease activity: derivation and validation in a post hoc study of anifrolumab phase II and III studies

Objectives This study aimed to derive and validate a cut-off for severe disease activity (SDA) using the SLE Disease Activity Score (SLE-DAS) and compare its accuracy and impact on health-related ...
lupus.bmj

LBP1 Interim results of an open-label, multicentre, Phase 1/2 study to assess YTB323 (rapcabtagene autoleucel), a CAR T-cell therapy, for severe refractory systemic lupus ...

Objective Patients with severe refractory systemic lupus erythematosus (srSLE) exhibit failure to respond to treatments, progressive organ damage, and high mortality. Traditionally manufactured ...
lupus.bmj

Type I interferons in host defence and inflammatory diseases

Type I interferons (IFN) can have dual and opposing roles in immunity, with effects that are beneficial or detrimental to the individual depending on whether IFN pathway activation is transient or ...
lupus.bmj

Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial

Objectives To identify predictors of overall lupus and lupus nephritis (LN) responses in patients with LN. Methods Data from the Aspreva Lupus Management Study (ALMS) trial cohort was used to identify ...